
Investing in a trusted Cardiac Diabetic Product List in India reflects one of the most resilient segments of the pharma industry that can give you endless profits. In this changing lifestyle and eating habits, the issues related to cardiovascular health are drastically increasing. These factors highly contribute to boosting the market size for cardiac diabetic products in India.
According to IBEF’s stated data in September 2025, it has been seen that there is a strong demand for cardiac and antidiabetic medications. Both these markets are growing at a CAGR of 13% and 9%, respectively. Therefore, for pharma professionals, this niche offers a wide scope for portfolio expansion and overall outcomes
So, for those who are planning to jump into this segment, Biofield Pharma is here add significant value. Backed by over two decades of formulation expertise, our company has launched a specialised division named Biorise, offering a premium Cardiac Diabetic Product List in India. Dive deeper into this blog and learn valuable insights into how our company can be an ideal choice for the PCD Franchise journey in cardiovascular drugs.
Biofield Pharma is a research-driven company with more than 25 years of experience in formulating high-quality products. Holding unwavering expertise in several categories, our company has launched an extensive range of cardiac diabetic products under the division name Biorise.
All these products include therapeutic combinations that can aid in maintaining good cardiovascular health. In addition, investing in this range can help you expand your pharma roots in a sustainable direction and gain significant profits. Our company has also been well-recognised for carrying a trusted Cardiac Diabetic Product List in India. Let’s have a glimpse of those products:
| Brand Name | Composition | Packaging |
|---|---|---|
| Amlogiv-M/25 | Amlodipine 5 Mg + Metoprolol Succinate 25 Mg Tablets | 10*10 Alu Alu |
| Amlogiv-M/50 | Amlodipine 5 Mg + Metoprolol Succinate 50 Mg Tablets | 10*10 Alu Alu |
| Etorcut 10 | Atorvastatin 10 Mg Tablets | 10*10 Alu Alu |
| Etorcut 20 | Atorvastatin 20 Mg Tablets | 10*15 Alu Alu |
| Beterpine-10 | Cilnidipine 10 Mg Tablets | 10*10 Alu Alu |
| Beterpine 20 | Cilnidipine 20 Mg Tablets | 10*10 Alu Alu |
| Amlogiv 2.5 | Amlodipine 2.5 Mg Tablets | 10*10 Blister |
| Amlogiv 5 | Amlodipine 5 Mg Tablets | 10*10 Alu Alu |
| Amlogiv At | Amlodipine 5 Mg + Atenolol 50 Mg Tablets | 10*10 Alu Alu |
| Etorcut C | Atorvastatin 10 Mg + Clopidogrel 75 Mg Tablets | 10*10 Alu Alu |
| Etorcut-C-20 | Atorvastatin 20 Mg + Clopidogrel 75 Mg Tablets | 10*10 Alu Alu |
| Etorcut F | Atorvastatin 10 Mg + Fenofibrate 160 Mg Tablets | 10*10 Alu Alu |
| Cletiway 75 | Clopidogrel 75 Mg Tablets | 10*15 Blister |
| Cletiway-A | Clopidogrel 75 Mg + Aspirin 75 Mg Tablets | 10*10 Strip Pack |
| Elsorite 20 | Olmesartan 20 Mg Tablets | 10*10 Alu Alu |
| Elsorite-H | Olmesartan 20 Mg + Hydrochlorothiazide 12.5 Mg Tablets | 10*10 Alu Alu |
| Elsorite A | Olmesartan 20 Mg + Amlodipine 5 Mg Tablets | 10*10 Alu Alu |
| Crestofine 20 | Rosuvastatin 20 Mg Tablets | 10*10 Alu Alu |
| Crestofine C-10 | Rosuvastatin 10 Mg + Clopidogrel 75 Mg Tablets | 10*10 Alu Alu |
| Crestofine-Gold 10 | Rosuvastatin 10 Mg + Clopidogrel 75 Mg + Aspirin 75 Mg Capsules | 10*15 Strip Pack |
| Crestofine C-20 | Rosuvastatin 20 Mg + Clopidogrel 75 Mg Capsules | 10*10 Alu Alu |
| Crestofine-F | Rosuvastatin 10 Mg + Fenofibrate 160 Mg Tablets | 10*10 Alu Alu |
| Crestofine-F | Rosuvastatin 20 Mg + Fenofibrate 160 Mg Tablets | 10*10 Alu Alu |
| Telsicap C | Telmisartan 40 Mg + Cilnidipine 10 Mg Tablets | 10*10 Alu Alu |
| Telsicap Am | Telmisartan 40 Mg + Amlodipine 5 Mg Tablets | 10*10 Alu Alu |
| Telsicap H | Telmisartan 40 Mg + Hydrochlorothiazide 12.5 Mg Tablets | 10*10 Alu Alu |
| Telsicap H 80 | Telmisartan 80 Mg + Hydrochlorothiazide 12.5 Mg Tablets | 10*10 Alu Alu |
| Telicap Ah | Telmisartan 40 Mg + Amlodipine 5 Mg + Hydrochlorothiazide 12.5 Mg Tablets | 10*10 Alu Alu |
In the Indian pharmaceutical sector, the cardiac diabetic segment remains one of the most stable and growth-oriented areas. With the increasing prevalence of cardiovascular disorders, the need for therapeutic medication is expected to rise in the upcoming years.
Here are some of the factors that drive the increase in demand for cardiac diabetic products, thereby making it a beneficial business segment:
Hence, with a strong understanding of market demand, Biofield Pharma offers a comprehensive range of Cardiac Diabetic Product List in India designed to support sustainable franchise growth and good heart health.
So, as discussed earlier, the cardiovascular drug market is growing rapidly; therefore, diving into this segment can indeed be lucrative. However, this niche can be competitive; therefore, to gain a remarkable presence, Biofield Pharma’s trusted division, Biorise, is here at your back. We offer a reliable Cardiac Diabetic Product List in India to help both seasoned and newcomers to excel in their business outcomes.
Investing in us can give you a seamless exposure to not only premium-quality products, but to various advantages that can mitigate the risks associated with building a successful PCD Pharma Franchise in cardiac diabetic products.
Safety and efficacy are the primary aspects that are considered while starting your pharma business. Therefore, to safeguard them, Biofield Pharma adheres to advanced technologies, innovative approaches, and strong R&D. From using pure raw materials and rigorous quality checks to proper documentation and final testing, each aspect is handled with care and precision.
Biofield Pharma has in-house manufacturing units certified by the WHO-GMP that smoothly meet the diverse order quantities. Selecting the order quantity as per your budget and targeting consumers, we ensure no delays in delivering the products to your doorstep. Our company aims to eliminate the risk of running out of stock so that you can establish a loyal relationship with your health professionals and end-users.
Working with ethical and transparent business practices, we intend to give a stable career to our investors. Our cardiac diabetic product franchise model is designed to generate financial gains through competitively priced products and reliable supply support. By focusing on long-term partnerships rather than short-term gains, Biofield Pharma’s Cardiac Diabetic PCD Pharma Franchise will help you build a steady and scalable pharma business.
Our company has an unparalleled presence across India, offering region-wise businessrights so that you grow without facing internal competition. Whether it’s about targeting rural or semi-urban areas for more profits or starting your journey in well-established urban areas, Biofield Pharma will provide you with a profitable location.
The following are some of the locations in which you can avail a monopoly-based cardiac diabetic franchise in India:
Biofield Pharma provides well-structured marketing and promotional support to help franchise associates establish a strong presence in their assigned territories. This includes professionally designed visual aids, product samples, MR bags, and festive gifts that assist in promoting doctor and distributor engagement. In this rapidly growing pharma niche and market-focused strategies, we support our partners in building brand visibility and achieving consistent business growth.
Are you ready to bring your entrepreneurial skills into play? If yes, schedule a meeting with Biofield Pharma, which carries a Cardiac Diabetic Product List in India. With some legal documents mentioned below, you can avail our franchise benefits and step into the world of profitability.
Here are the contact details. Without wasting time, connect with us today!
Address – Scf 466, First Floor, Sector – 13, Chandigarh 160101
Mobile Number – +91-9888421594 or +91-7743005525
Email – connect.biofield@gmail.com
